Prolixin Decanoate

Chorea, Depression, Sedation + 4 more

Treatment

1 FDA approval

20 Active Studies for Prolixin Decanoate

What is Prolixin Decanoate

Fluphenazine

The Generic name of this drug

Treatment Summary

Fluphenazine is a type of anti-psychotic medication used to treat mental disorders such as psychosis. It works in a similar way to chlorpromazine and helps to reduce symptoms such as hallucinations, delusions, and anxiety.

Fluphenazine Hydrochloride

is the brand name

image of different drug pills on a surface

Prolixin Decanoate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fluphenazine Hydrochloride

Fluphenazine

1987

181

Approved as Treatment by the FDA

Fluphenazine, also known as Fluphenazine Hydrochloride, is approved by the FDA for 1 uses including Schizophrenia .

Schizophrenia

Helps manage Psychosis

Effectiveness

How Prolixin Decanoate Affects Patients

Fluphenazine is a drug used to treat schizophrenia and other psychotic disorders. It has not been found to help with managing behavioral problems in people with mental disabilities.

How Prolixin Decanoate works in the body

Fluphenazine works on the brain to reduce activity. It blocks receptors that are responsible for stimulating nerve cells. This has effects on the hormones released by the hypothalamus and pituitary gland, as well as on the reticular activating system, which affects basic metabolism, body temperature, wakefulness, and other functions.

When to interrupt dosage

The suggested dosage of Prolixin Decanoate is contingent upon the identified disorder, such as Schizophrenia, Gilles de la Tourette's Syndrome and Sedation therapy. The amount of dosage differs, as per the delivery approach (e.g. Tablet, film coated - Oral or Intramuscular) catalogued in the following table.

Condition

Dosage

Administration

Depression

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Schizophrenia

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Sedation therapy

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Tourette Syndrome

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Chorea

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Sedation

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Huntington Disease

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous, Intramuscular; Subcutaneous, Solution

Warnings

Prolixin Decanoate Contraindications

Condition

Risk Level

Notes

Brain Injuries

Do Not Combine

Disease

Do Not Combine

Liver Damage

Do Not Combine

Mental Depression

Do Not Combine

Hypnotics

Do Not Combine

Brain Injuries

Do Not Combine

Coma

Do Not Combine

There are 20 known major drug interactions with Prolixin Decanoate.

Common Prolixin Decanoate Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Fluphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Fluphenazine.

Azelastine

Major

Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Fluphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Fluphenazine is combined with Deutetrabenazine.

image of a doctor in a lab doing drug, clinical research

Prolixin Decanoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Prolixin Decanoate?

640 active clinical trials are investigating the potential of Prolixin Decanoate to mitigate Huntington Disease, Sedation therapy and Chorea.

Condition

Clinical Trials

Trial Phases

Sedation therapy

0 Actively Recruiting

Sedation

2 Actively Recruiting

Early Phase 1, Not Applicable

Tourette Syndrome

0 Actively Recruiting

Depression

296 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Huntington Disease

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Chorea

0 Actively Recruiting

Schizophrenia

30 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Prolixin Decanoate Reviews: What are patients saying about Prolixin Decanoate?

5

Patient Review

3/3/2008

Prolixin Decanoate for Schizophrenia

5

Patient Review

9/29/2015

Prolixin Decanoate for Mental Disorder with Loss of Normal Personality & Reality

This shot has made a world of difference for my mother and our family. We stopped all her other medications and now only use this one every four weeks.

4.3

Patient Review

8/14/2014

Prolixin Decanoate for Mental Disorder with Loss of Normal Personality & Reality

When I first got this injection, it was like a huge weight had been lifted off of me. It really worked wonders for me and helped immensely. The only downside is that you have to take another medication to counteract the side effects, which causes terrible dry mouth.

3

Patient Review

5/25/2011

Prolixin Decanoate for Schizophrenia

I've used this for 10 years to manage my illness, but now that I have early onset Alzheimer's, I wonder if it is still safe for me to take.

1

Patient Review

5/29/2012

Prolixin Decanoate for Mental Disorder with Loss of Normal Personality & Reality

Prolixin Decanoate Inj caused neuroleptic malignant syndrome which resulted in paralysis. I'm lucky to be alive after just one injection of this stuff.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about prolixin decanoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you administer fluphenazine?

"This medication is typically given as a deep intramuscular injection into the buttock area, usually at doses of 12.5 mg to 100 mg, given every two to five weeks."

Answered by AI

What is prolixin decanoate used for?

"This fluphenazine medication works for long periods of time to treat mental and mood problems like chronic schizophrenia."

Answered by AI

How do I start prolixin decanoate?

"Initiation: 6.25 mg IM

Dose adjustments: 6.25 to 12.5 mg increments every two weeks until the target dose is reached."

Answered by AI

What is the side effect of prolixin?

"you may experience: drowsiness, lethargy, dizziness, lightheadedness, nausea, loss of appetite, sweating, dry mouth, blurred vision, headache, and constipation. If you have any of these symptoms, tell your doctor or pharmacist. Dizziness and lightheadedness can make you more likely to fall."

Answered by AI

Clinical Trials for Prolixin Decanoate

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Prolixin Decanoate clinical trials?

We made a collection of clinical trials featuring Prolixin Decanoate, we think they might fit your search criteria.
Go to Trials
Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Have you considered Prolixin Decanoate clinical trials?

We made a collection of clinical trials featuring Prolixin Decanoate, we think they might fit your search criteria.
Go to Trials
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL

This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.

Recruiting
Has No Placebo

Mayo Clinic in Florida

Juan C. Cardenas Rosales, MD

Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA

The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Phase 2
Recruiting

University of California, Los Angeles

Have you considered Prolixin Decanoate clinical trials?

We made a collection of clinical trials featuring Prolixin Decanoate, we think they might fit your search criteria.
Go to Trials